Posts

Alkermes Advances Alixorexton to Phase 3 for Narcolepsy with Strong Mid-Stage Data

on
Alkermes' alixorexton met dual primary endpoints in Phase II Vibrance-1 study for narcolepsy type 2 (NT2), showing significant improvements in mean sleep latency and daytime sleepiness at 18-mg and 14-mg doses. Truist Securities analysts described the Phase II data as 'highly competitive' and sufficient for Phase III success. Phase III Brilliance Studies for alixorexton in NT1 and NT2 initiated on April 1-2, 2026. Alkermes acquired Avadel for $2.1 billion, adding approved narcolepsy drug Lumryz expected to generate $265-275 million in 2025. Alixorexton, an oral orexin 2 receptor agonist, is also being tested for narcolepsy type 1 (NT1) and idiopathic hypersomnia (IH). No recent news found on Boehringer's antibody deal in provided search results. Sources:

Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU

on

Five Burning Questions for Isomorphic Labs After $2.1B Raise

on

INNOVOTEX Appoints Jonathan Arambula to Executive Chairman

on

Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026

on

Quest Analytics Appoints Chris Lance as Chief Product Officer to Drive AI Innovation

on

Biotech's IPO Tide Turning Amid M&A Surge

on

Viewpoints: How iRhythm Technologies is Patching into the Future of Arrhythmia Detection

on

Roche Secures Second CE Mark for Eli Lilly-Co-Developed Alzheimer's Blood Test pTau217 in Europe

on

FDA Commissioner Marty Makary to Resign, Capping Turbulent Tenure: Report

on

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

on

GSK acquires Siran Biotechnology for $1 billion to expand beyond weight-loss with siRNA therapy

on

FDA Publishes Complete Response Letters Revealing Manufacturing and Data Gaps as Primary Reasons for Drug Rejections

on